← All trials
NCT04780451
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 16, 2020
- Primary completion
- Dec 20, 2020
- Completion date
- Mar 2, 2021
- First posted
- Mar 3, 2021
- Last posted
- Mar 3, 2021
- Enrollment
- 40
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Gdansk University of Physical Education and SportLead sponsor
- Moorgreen Hospital, SouthamptonCollaborator
- Medical University of GdanskCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.